Physician profile
Cortnee L Roman
NPI 1356585210
$373,560.33
in general payments reported to CMS, 2019-2025
42 companies · $101K in 2025
The $101K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $63K · 2022: $47K · 2023: $80K · 2024: $83K · 2025: $101K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $137K · Travel and Lodging: $56K · Consulting Fee: $52K · Food and Beverage: $19K · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $137,118.50 |
| Travel and Lodging | $55,685.59 |
| Consulting Fee | $52,221.00 |
| Food and Beverage | $18,989.68 |
| Education | $127.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $155,083.18 | 2021-2025 | Vumerity, Tysabri, Tysabri |
| Tg Therapeutics, INC. | $77,211.33 | 2021-2025 | Briumvi |
| Amgen INC. | $43,626.75 | 2021-2025 | Uplizna |
| E.R. Squibb & Sons, L.L.C. | $28,548.03 | 2021-2025 | Zeposia |
| Alexion Pharmaceuticals, INC. | $23,000.40 | 2021-2025 | Ultomiris, Soliris |
| Emd Serono, INC. | $9,874.31 | 2021-2025 | Mavenclad, Mavenclad |
| Ucb, INC. | $8,625.60 | 2023-2025 | Zilbrysq, Rystiggo |
| Celgene Corporation | $8,606.01 | 2021-2025 | Zeposia |
| Genentech USA, INC. | $6,494.71 | 2021-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Novartis Pharmaceuticals Corporation | $6,051.66 | 2023-2025 | |
| Horizon Therapeutics Plc | $1,514.93 | 2021-2023 | Uplizna |
| Abbvie INC. | $1,121.55 | 2021-2025 | |
| Banner Life Sciences, LLC | $913.11 | 2021-2024 | |
| Genzyme Corporation | $645.23 | 2021-2025 | |
| Argenx US, INC. | $302.82 | 2024-2025 | Vyvgart Hytrulo |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $292.64 | 2022-2025 | |
| Axsome Therapeutics, INC. | $174.34 | 2023-2025 | Sunosi |
| Janssen Scientific Affairs, LLC | $166.81 | 2024-2025 | |
| Genentech, INC. | $166.19 | 2023-2025 | Ocrevus, Ocrevus Zunovo |
| Pfizer INC. | $149.77 | 2023-2025 | |
| Janssen Biotech, INC. | $114.81 | 2025 | |
| Eisai INC. | $101.40 | 2024-2025 | |
| Csl Behring | $92.59 | 2022-2025 | Hizentra |
| Lilly USA, LLC | $90.36 | 2021-2025 | Kisunla |
| Abbott Laboratories | $88.23 | 2024 | Freestyle Libre 3 |
| Ani Pharmaceuticals, INC. | $83.04 | 2023-2024 | Purified Cortrophin Gel |
| Vanda Pharmaceuticals INC. | $71.32 | 2024-2025 | Ponvory |
| Cycle Pharmaceuticals INC | $43.56 | 2025 | Tascenso Odt, Bafiertam |
| Mylan Specialty L.P. | $38.82 | 2024 | |
| Janssen Pharmaceuticals, INC | $32.34 | 2021-2022 | |
| Merz Pharmaceuticals, LLC | $32.12 | 2025 | Inbrija, Ampyra, Xeomin |
| Grifols USA, LLC | $26.62 | 2023 | Gamunex-C |
| Allergan, INC. | $24.64 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $24.25 | 2025 | Ajovy |
| Lundbeck LLC | $19.33 | 2021 | |
| Sandoz INC. | $18.04 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $16.93 | 2024 | Nuedexta |
| Jazz Pharmaceuticals INC. | $15.72 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.21 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.96 | 2023 | Quviviq |
| Neurelis, INC. | $13.77 | 2025 | Valtoco |
| Azurity Pharmaceuticals, INC. | $12.90 | 2023 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cortnee Roman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.